Physician profile
Shiraz Butt
NPI 1578556973
$367.96
in general payments reported to CMS, 2019-2025
9 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.00 · 2020: $19.99 · 2021: $93.60 · 2024: $75.20 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $93.60 | 2021 | |
| Merck Sharp & Dohme LLC | $69.76 | 2025 | |
| Lundbeck LLC | $62.41 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $29.11 | 2024 | Cobenfy |
| Janssen Pharmaceuticals, INC | $24.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.12 | 2024 | Uzedy |
| Alkermes, INC. | $22.32 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.97 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $19.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiraz Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.